R&D channel feed – Endpoints News

R&D channel feed

Longtime Sanofi R&D chief Elias Zerhouni is on his way out, handing the research reins to Roche vet John Reed

8 years ago

FDA orders a partial hold on Epizyme’s lead cancer drug tazemetostat following T-cell lymphoma case

8 years ago

Bankrupt and weary, diet pill maker Orexigen to sell for $75M to Nalpropion

8 years ago

Pfizer hits stumbling block on Herceptin rival, but wins 'breakthrough' status on MenB vaccine

8 years ago

Prothena’s lead drug NEOD001 just imploded in 2 late-stage studies — and there’s nothing left to salvage

8 years ago

Novartis CEO Vas Narasimhan is raising the bar on second-gen cancer drug studies

8 years ago

With Gilenya generics looming, Novartis’ siponimod team buffs up the MS data package being prepped for the FDA

8 years ago

Biogen pays $1B cash to enlist Ionis on a new drug discovery campaign — but can it deliver fast enough for analysts?

8 years ago

Novartis poaches Bristol-Myers/Amgen vet John Tsai for top drug development post in a $9B organization

8 years ago

Bluebird’s gene therapy for beta-thalassemia falls short of a cure, but still wows in 22 patients

8 years ago

Full FDA letter in hand, Solid Bio says it's working to reverse clinical hold on its DMD gene therapy

8 years ago

GlaxoSmithKline’s Hal Barron poaches Genentech’s top cancer drug dealmaker for his new R&D team

8 years ago

Turning cold tumors hot, Checkmate Pharma outlines its initial success story at #AACR18

8 years ago

Blockbuster ambitions: Amgen/Novartis team lines up more promising PhIII erenumab data for some of the toughest migraine patients

8 years ago

J&J dumps a failed PhIII antibiotic program picked up in Actelion buyout

8 years ago

In light of Incyte's epacadostat debacle, NewLink scraps PhIII plans for its own IDO drug

8 years ago

Bristol-Myers invites J&J into an alliance of giants on cardio drug development/commercialization program

8 years ago

#AACR18: Roche spotlights promising subgroup responses for lung cancer combo with Tecentriq

8 years ago

Who won big at #AACR18? Merck surges on Keytruda/chemo combo while Bristol-Myers shares tumble on comparison

8 years ago

#AACR: Merck spotlights pivotal Keytruda/chemo data, hoping to break down skepticism to its frontline lung cancer duo

8 years ago

#AACR: Bristol-Myers tunes out static, broadcasts impressive results for Opdivo/Yervoy lung cancer combo

8 years ago

#AACR18 round 1: Merck takes a direct swing at Bristol-Myers with adjuvant melanoma data for Keytruda

8 years ago

Alnylam flags looming FDA application for givosiran, adding another round of stellar efficacy data from early study

8 years ago

After patient deaths, failed partnerships and a stock scandal, Hanmi finally gives up on controversial olmutinib. What did we learn?

8 years ago

First page Previous page 275 276 277278279 280 281 Next page Last page